ALKBH5 and cancer: ALKBH5-mediated FOXO1 m6A demethylation increases the expression of superoxide dismutase 2 and leads to a lower ROS level, thus promoting the maintenance of cancer stem cell characteristics and doxorubicin resistance in TNBC.